Corilagin is a polyphenol, ellagitannin and hydrolyzable tannin that can be isolated from a variety of plants. This compound displays the ability to inhibit squalene epoxidase, a key enzyme in cholesterol synthesis, and NFκB pathway activation and also prevent the release of TNF-α at an IC50 of 76 μM. Additional studies show that Corilagin significantly inhibits type 1 plasminogen activator inhibitor (PAI-1) in rat plasma. Also has been reported to result in an increase in plasma tissue-type plasminogen activator (tPA) which results in the thrombolytic effect of Corilagin. In other studies, Corilagin showed some other pharmaceutical activities, such as antiviral effects in vitro, antinociceptive activity, anti-hyperalgesic activity, and action of anti-tumor in hepatocellular carcinoma and ovarian cancer.

Camostat mesilate (FOY-305) is a synthetic f low-molecular weight protease inhibitor. It is able to inhibit trypsin, prostasin, matriptase and plasma kallikrein. In addition camostat attenuates airway epithelial sodium channel function and enhances mucociliary clearance. Camostat mesilate tablets (FOIPAN®) are approved in Japan and used for the treatment of remission of acute symptoms of chronic pancreatitis and postoperative reflux esophagitis.

Camostat mesilate (FOY-305) is a synthetic f low-molecular weight protease inhibitor. It is able to inhibit trypsin, prostasin, matriptase and plasma kallikrein. In addition camostat attenuates airway epithelial sodium channel function and enhances mucociliary clearance. Camostat mesilate tablets (FOIPAN®) are approved in Japan and used for the treatment of remission of acute symptoms of chronic pancreatitis and postoperative reflux esophagitis.